SG11202100983XA - Method of producing tetracyclic compound - Google Patents
Method of producing tetracyclic compoundInfo
- Publication number
- SG11202100983XA SG11202100983XA SG11202100983XA SG11202100983XA SG11202100983XA SG 11202100983X A SG11202100983X A SG 11202100983XA SG 11202100983X A SG11202100983X A SG 11202100983XA SG 11202100983X A SG11202100983X A SG 11202100983XA SG 11202100983X A SG11202100983X A SG 11202100983XA
- Authority
- SG
- Singapore
- Prior art keywords
- tetracyclic compound
- producing
- producing tetracyclic
- compound
- tetracyclic
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B61/00—Other general methods
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2018165313 | 2018-09-04 | ||
PCT/JP2019/034543 WO2020050241A1 (en) | 2018-09-04 | 2019-09-03 | Method of producing tetracyclic compound |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202100983XA true SG11202100983XA (en) | 2021-03-30 |
Family
ID=69722303
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202100983XA SG11202100983XA (en) | 2018-09-04 | 2019-09-03 | Method of producing tetracyclic compound |
Country Status (14)
Country | Link |
---|---|
US (1) | US11939322B2 (en) |
EP (1) | EP3848361A4 (en) |
JP (1) | JP7167171B2 (en) |
KR (1) | KR102635225B1 (en) |
CN (1) | CN112585126B (en) |
AR (1) | AR116113A1 (en) |
AU (1) | AU2019337018B2 (en) |
BR (1) | BR112021001145A2 (en) |
CA (1) | CA3107270A1 (en) |
IL (1) | IL281079B1 (en) |
MX (1) | MX2021002311A (en) |
SG (1) | SG11202100983XA (en) |
TW (1) | TWI825163B (en) |
WO (1) | WO2020050241A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2023008735A (en) | 2021-01-29 | 2023-08-01 | Chugai Pharmaceutical Co Ltd | Drug composition for treating pediatric cancers. |
Family Cites Families (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS506987B1 (en) | 1970-02-17 | 1975-03-19 | ||
JPS4918630B1 (en) | 1970-07-29 | 1974-05-11 | ||
JPS5859712U (en) | 1981-10-16 | 1983-04-22 | ニチバン株式会社 | label pasting machine |
JPH0892090A (en) | 1994-07-26 | 1996-04-09 | Tanabe Seiyaku Co Ltd | Medicinal composition |
DE69505470T2 (en) | 1994-08-04 | 1999-05-12 | F. Hoffmann-La Roche Ag, Basel | Pyrrolocarbazole |
IL126762A0 (en) | 1996-05-01 | 1999-08-17 | Lilly Co Eli | Halo-substituted protein kinase c inhibitors |
RU2238937C2 (en) | 1998-12-24 | 2004-10-27 | Фудзисава Фармасьютикал Ко., Лтд. | Derivatives of imidazole, pharmaceutical composition and method for prophylaxis and/or treatment based on thereof |
JP2002544275A (en) | 1999-05-14 | 2002-12-24 | ジ・オーストラリアン・ナショナル・ユニバーシティー | Compounds and methods of treatment |
GB0030417D0 (en) | 2000-12-13 | 2001-01-24 | Pharma Mar Sa | An anticancer lead compound isolated from a New Zealand ascidian |
FR2841138B1 (en) | 2002-06-25 | 2005-02-25 | Cll Pharma | SOLID PHARMACEUTICAL COMPOSITION COMPRISING A LIPOPHILIC ACTIVE INGREDIENT, ITS PREPARATION PROCESS |
AU2004258801A1 (en) | 2003-02-28 | 2005-02-03 | Inotek Pharmaceuticals Corporation | Tetracyclic Benzamide Derivatives and methods of use thereof |
PT1454992E (en) | 2003-03-07 | 2006-09-29 | Ist Naz Stud Cura Dei Tumori | KINASE-TEST OF ANAPLASTIC LYMPHOMA, REAGENTS AND COMPOSITIONS |
GB0305929D0 (en) | 2003-03-14 | 2003-04-23 | Novartis Ag | Organic compounds |
JP4836788B2 (en) | 2003-07-23 | 2011-12-14 | エグゼリクシス, インコーポレイテッド | Undifferentiated lymphoma kinase modulators and methods of use thereof |
US7378414B2 (en) | 2003-08-25 | 2008-05-27 | Abbott Laboratories | Anti-infective agents |
MXPA06005702A (en) | 2003-11-21 | 2006-08-17 | Novartis Ag | 1h-imidazoquinoline derivatives as protein kinase inhibitors. |
CN100548986C (en) | 2003-12-12 | 2009-10-14 | 默克弗罗斯特加拿大有限公司 | Cathepsin cysteine protease inhibitors |
US7868036B2 (en) | 2004-03-19 | 2011-01-11 | Novartis Ag | Organic compounds |
US20090155903A1 (en) | 2004-03-19 | 2009-06-18 | Myriad Genetics, Incorporated | Pharmaceutical composition and method |
AU2005230847B2 (en) | 2004-03-31 | 2012-11-08 | Exelixis, Inc. | Anaplastic lymphoma kinase modulators and methods of use |
WO2005121102A2 (en) | 2004-06-02 | 2005-12-22 | Pharmacyclics, Inc. | Factor viia inhibitor |
RS51362B (en) | 2004-08-26 | 2011-02-28 | Pfizer Inc. | Enantiomerically pure aminoheteroaryl compunds as protein kinase inhibitors |
US7091202B2 (en) | 2004-09-15 | 2006-08-15 | Bristol-Myers Squibb Company | 4-arylspirocycloalkyl-2-aminopyrimidine carboxamide KCNQ potassium channel modulators |
GB0517329D0 (en) | 2005-08-25 | 2005-10-05 | Merck Sharp & Dohme | Stimulation of neurogenesis |
KR20080056288A (en) | 2005-11-07 | 2008-06-20 | 아이알엠 엘엘씨 | Compounds and compositions as ppar modulators |
US7601716B2 (en) | 2006-05-01 | 2009-10-13 | Cephalon, Inc. | Pyridopyrazines and derivatives thereof as ALK and c-Met inhibitors |
US8063225B2 (en) | 2006-08-14 | 2011-11-22 | Chembridge Corporation | Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders |
MX2009004426A (en) | 2006-10-23 | 2009-08-12 | Cephalon Inc | Fused bicyclic derivatives of 2,4-diaminopyrimidine as alk and c-met inhibitors. |
CN101687873A (en) | 2007-04-17 | 2010-03-31 | 百时美施贵宝公司 | 11 beta-hydroxysteroid dehydrogenase type i inhibitors with annelated heterocycles |
TWI389893B (en) | 2007-07-06 | 2013-03-21 | Astellas Pharma Inc | Di (arylamino) ary1 compound |
EP2176231B1 (en) | 2007-07-20 | 2016-10-19 | Nerviano Medical Sciences S.r.l. | Substituted indazole derivatives active as kinase inhibitors |
JP5583592B2 (en) | 2007-11-30 | 2014-09-03 | ニューリンク ジェネティクス コーポレイション | IDO inhibitor |
WO2009113420A1 (en) | 2008-03-13 | 2009-09-17 | 第一三共株式会社 | Improvement of dissolvability of preparation containing olmesartan medoxomil |
CN102574830A (en) | 2009-05-07 | 2012-07-11 | 阿斯利康(瑞典)有限公司 | Substituted 1-cyanoethylheterocyclylcarboxamide compounds 750 |
AR077025A1 (en) | 2009-06-10 | 2011-07-27 | Chugai Pharmaceutical Co Ltd | TETRACICLIC COMPOUNDS |
GB0910046D0 (en) | 2009-06-10 | 2009-07-22 | Glaxosmithkline Biolog Sa | Novel compositions |
US8609097B2 (en) | 2009-06-10 | 2013-12-17 | Hoffmann-La Roche Inc. | Use of an anti-Tau pS422 antibody for the treatment of brain diseases |
TWI526441B (en) | 2010-08-20 | 2016-03-21 | 中外製藥股份有限公司 | Composition comprising tetracyclic compounds |
JP5006987B2 (en) | 2010-11-22 | 2012-08-22 | 中外製薬株式会社 | Medicine containing tetracyclic compound |
AU2013321235B2 (en) | 2012-09-25 | 2017-07-20 | Chugai Seiyaku Kabushiki Kaisha | RET inhibitor |
CN113416179A (en) | 2014-04-25 | 2021-09-21 | 中外制药株式会社 | Novel crystal of tetracyclic compound |
MX2016013809A (en) | 2014-04-25 | 2017-03-09 | Chugai Pharmaceutical Co Ltd | Preparation containing tetracyclic compound at high dose. |
CA2942186C (en) | 2014-06-18 | 2023-06-27 | Chugai Seiyaku Kabushiki Kaisha | Pharmaceutical composition comprising non-ionic surfactants |
TWI718102B (en) | 2014-08-08 | 2021-02-11 | 日商中外製藥股份有限公司 | Amorphous body of tetracyclic compound |
CN104402862B (en) * | 2014-11-12 | 2016-10-05 | 苏州明锐医药科技有限公司 | Ai Li is for the preparation method of Buddhist nun |
US9573932B2 (en) | 2015-03-02 | 2017-02-21 | Yong Xu | Synthesis of intermediates in the preparation of ALK inhibitor |
WO2017073706A1 (en) | 2015-10-30 | 2017-05-04 | 中外製薬株式会社 | DIHYDRONAPHTHO[2,3-b]BENZOFURAN DERIVATIVE |
CN107033124B (en) | 2017-04-21 | 2019-09-20 | 湖南博奥德药业有限公司 | A kind of Ai Le replaces the preparation method of Buddhist nun |
CN106928185B (en) | 2017-04-21 | 2019-09-20 | 湖南博奥德药业有限公司 | A kind of Ai Le replaces the preparation method of Buddhist nun |
CN106928184B (en) | 2017-04-21 | 2019-09-20 | 湖南博奥德药业有限公司 | A kind of Ai Le replaces the preparation method of Buddhist nun |
-
2019
- 2019-09-03 CA CA3107270A patent/CA3107270A1/en active Pending
- 2019-09-03 JP JP2020541220A patent/JP7167171B2/en active Active
- 2019-09-03 KR KR1020217005965A patent/KR102635225B1/en active IP Right Grant
- 2019-09-03 US US17/271,437 patent/US11939322B2/en active Active
- 2019-09-03 IL IL281079A patent/IL281079B1/en unknown
- 2019-09-03 MX MX2021002311A patent/MX2021002311A/en unknown
- 2019-09-03 AR ARP190102518A patent/AR116113A1/en unknown
- 2019-09-03 AU AU2019337018A patent/AU2019337018B2/en active Active
- 2019-09-03 TW TW108131697A patent/TWI825163B/en active
- 2019-09-03 CN CN201980056366.1A patent/CN112585126B/en active Active
- 2019-09-03 EP EP19856540.0A patent/EP3848361A4/en active Pending
- 2019-09-03 WO PCT/JP2019/034543 patent/WO2020050241A1/en unknown
- 2019-09-03 SG SG11202100983XA patent/SG11202100983XA/en unknown
- 2019-09-03 BR BR112021001145-5A patent/BR112021001145A2/en unknown
Also Published As
Publication number | Publication date |
---|---|
JPWO2020050241A1 (en) | 2021-08-30 |
US11939322B2 (en) | 2024-03-26 |
BR112021001145A2 (en) | 2021-04-20 |
AU2019337018B2 (en) | 2024-03-07 |
WO2020050241A1 (en) | 2020-03-12 |
EP3848361A1 (en) | 2021-07-14 |
TWI825163B (en) | 2023-12-11 |
TW202024050A (en) | 2020-07-01 |
CA3107270A1 (en) | 2020-03-12 |
KR102635225B1 (en) | 2024-02-07 |
IL281079B1 (en) | 2024-08-01 |
JP7167171B2 (en) | 2022-11-08 |
AR116113A1 (en) | 2021-03-31 |
CN112585126A (en) | 2021-03-30 |
EP3848361A4 (en) | 2022-06-15 |
CN112585126B (en) | 2024-05-07 |
KR20210053890A (en) | 2021-05-12 |
US20220372025A1 (en) | 2022-11-24 |
MX2021002311A (en) | 2021-04-28 |
IL281079A (en) | 2021-04-29 |
AU2019337018A1 (en) | 2021-03-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL269651A (en) | Improved method of producing collagenase | |
HUE057666T2 (en) | Method for preparing intermediate of 4-methoxypyrrole derivative | |
GB201806072D0 (en) | Methods of manufacture | |
SG11202103664WA (en) | Process for producing perfluoroalkyne compound | |
GB201804594D0 (en) | Bonegraft substituteand method of manufacture | |
PL3755681T3 (en) | Method of 4-boronophenylalanine production | |
PL3733651T3 (en) | Method for producing calcobutrol | |
IL287063A (en) | Method for producing biotissue-like structure | |
IL281431A (en) | Methods of producing pyrazole compounds | |
EP3257834A4 (en) | Method of producing c2-c4 carbonyl compounds | |
EP3643701A4 (en) | Method for producing compound | |
GB201802839D0 (en) | Method of manufacture | |
GB201805904D0 (en) | Methods of Manufacture | |
IL275434B (en) | Method for producing thiocarboxamidine salt compound | |
SG11202101704VA (en) | Method of producing piperylene | |
PT3864118T (en) | Method of producing biodiesel | |
EP3891099C0 (en) | Method of preparing phosphorus | |
SG11202106891PA (en) | Method for producing cyclobutene | |
SG11202100983XA (en) | Method of producing tetracyclic compound | |
GB201809783D0 (en) | A method of producing a structure | |
ZA201808254B (en) | Method for producing crystal of uracil compound | |
HUE065555T2 (en) | Method for producing butadiene compound | |
SG11201907182QA (en) | Method for producing perfluoroalkadiene compounds | |
IL279070A (en) | Method for producing diarylpyridine derivatives | |
SG11202103673UA (en) | Method for producing perfluorocycloalkene compound |